Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone

Molecular Psychiatry

Volumn 20, Issue 6, 2015, Pages 744-754

  Cheng, Y ^a   Rodriguiz, R M ^b   Murthy, S R K ^a   Senatorov, V ^a   Thouennon, E ^a   Cawley, N X ^a   Aryal, D K ^b   Ahn, S ^a   Lecka Czernik, B ^c   Wetsel, W C ^b,d   Loh, Y P ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Department of Psychiatry and Behavioral Sciences ^*  (United States)

^c MEDICAL COLLEGE OF OHIO   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLECORTIN; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR ALPHA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CARBOXYPEPTIDASE H; DOUBLECORTIN PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NEUROPEPTIDE; SUCROSE; SWEETENING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; HIPPOCAMPAL NEURONAL CULTURE; HIPPOCAMPUS; IMMOBILIZATION STRESS; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRESS; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; FOOD PREFERENCE; GENETICS; MENTAL STRESS; METABOLISM; PSYCHOLOGY; SWIMMING; TRANSGENIC MOUSE;

ANIMALS; CARBOXYPEPTIDASE H; CELLS, CULTURED; DEPRESSION; DISEASE MODELS, ANIMAL; FOOD PREFERENCES; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NEUROGENESIS; NEUROPEPTIDES; STRESS, PSYCHOLOGICAL; SUCROSE; SWEETENING AGENTS; SWIMMING; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84929959524     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.136     Document Type: Article

References (58)

1. van Praag HM. Can stress cause depression? World J Biol Psychiatry 2005; 6: 5-22.
2. Maes MaM HY. The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1994.
3. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522.
4. Jiang C, Salton SR. The role of neurotrophins in major depressive disorder. Transl Neurosci 2013; 4: 46-58.
5. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
6. Turner CA, Watson SJ, Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 2012; 76: 160-174.
7. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
8. Voorhees JL, Tarr AJ, Wohleb ES, Godbout JP, Mo X, Sheridan JF et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One 2013; 8: E58488.
9. McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000; 886: 172-189.
10. Duman RS, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46: 1181-1191.
11. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006; 16: 239-249.
12. Kempton MJ, Salvador Z, Munafo MR, Geddes JR, Simmons A, Frangou S et al. Structural neuroimaging studies in major depressive disorder. Meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011; 68: 675-690.
13. Arnone D, McKie S, Elliott R, Juhasz G, Thomas EJ, Downey D et al. Statedependent changes in hippocampal grey matter in depression. Mol Psychiatry 2012; 18: 1265-1272.
14. Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, John Mann J et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009; 34: 2376-2389.
15. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-522.
16. Djavadian RL. Serotonin and neurogenesis in the hippocampal dentate gyrus of adult mammals. Acta Neurobiol Exp (Wars) 2004; 64: 189-200.
17. Sen S, Duman R, Sanacora. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-532.
18. Turner CA, Clinton SM, Thompson RC, Watson SJ Jr, Akil H. Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Nati Acad Sci USA 2011; 108: 8021-8025.
19. Turner CA, Calvo N, Frost DO, Akil H, Watson SJ. The fibroblast growth factor system is downregulated following social defeat. Neurosci Lett 2008; 430: 147-150.
20. Elsayed M, Banasr M, Duric V, Fournier NM, Licznerski P, Duman RS. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 2012; 72: 258-265.
21. Cheng Y, Cawley NX, Loh YP. Carboxypeptidase E/NF1: a new neurotrophic factor against oxidative stress-induced apoptotic cell death mediated by ERK and PI3-K/AKT pathways. PLoS One 2013; 8: E71578.
22. Fricker LD, Snyder SH. Enkephalin convertase: purification and characterization of a specific enkephalin-synthesizing carboxypeptidase localized to adrenal chromaffin granules. Proc Natl Acad Sci USA 1982; 79: 3886-3890.
23. Hook VY, Eiden LE, Brownstein MJ. A carboxypeptidase processing enzyme for enkephalin precursors. Nature 1982; 295: 341-342.
24. Rodriguiz RM, Wilkins JJ, Creson TK, Biswas R, Berezniuk I, Fricker AD et al. Emergence of anxiety-like behaviours in depressive-like Cpefat/fat mice. Int J Neuropsychopharmacol 2013; 16: 1623-1634.
25. Cawley NX, Wetsel WC, Murthy SR, Park JJ, Pacak K, Loh YP. New roles of carboxypeptidase E in endocrine and neural function and cancer. Endocr Rev 2012; 33: 216-253.
26. Woronowicz A, Cawley NX, Loh YP. Carbamazepine prevents hippocampal neurodegeneration in mice lacking the neuroprotective protein, carboxypetidase E. Clinic Pharmacol Biopharmaceut 2012; S1: 002; doi:10. 4172/2167-065X. S1-002.
27. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151.
28. Eissa Ahmed AA, Al-Rasheed NM, Al-Rasheed NM. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol 2009; 20: 635-642.
29. Rasgon NL, Kenna HA, Williams KE, Powers B, Wroolie T, Schatzberg AF. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Scientific World J 2010; 10: 321-328.
30. Murthy SR, Thouennon E, Li WS, Cheng Y, Bhupatkar J, Cawley NX et al. Carboxypeptidase E protects hippocampal neurons during stress in male mice by up-regulating pro-survival BCL2 protein expression. Endocrinology 2013; 154: 3284-3293.
31. Meerlo P, Easton A, Bergmann BM, Turek FW. Restraint increases prolactin and REM sleep in C57BL/6J mice but not in BALB/cJ mice. Am J Physiol Reg I 2001; 281: R846-R854.
32. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987; 93: 358-364.
33. Fukui M, Rodriguiz RM, Zhou J, Jiang SX, Phillips LE, Caron MG et al. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci 2007; 27: 10520-10529.
34. Woronowicz A, Koshimizu H, Chang SY, Cawley NX, Hill JM, Rodriguiz RM et al. Absence of carboxypeptidase E leads to adult hippocampal neuronal degeneration and memory deficits. Hippocampus 2008; 18: 1051-1063.
35. Cawley NX, Zhou J, Hill JM, Abebe D, Romboz S, Yanik T et al. The carboxypeptidase E knockout mouse exhibits endocrinological and behavioral deficits. Endocrinology 2004; 145: 5807-5819.
36. Jimenez SK, Sheikh F, Jin Y, Detillieux KA, Dhaliwal J, Kardami E et al. Transcriptional regulation of FGF-2 gene expression in cardiac myocytes. Cardiovasc Res 2004; 62: 548-557.
37. Tang W, Pan Q, Sun F, Ma J, Tang S, Le K et al. Involvement of Sp1 binding sequences in basal transcription of the rat fibroblast growth factor-2 gene in neonatal cardiomyocytes. Life Sci 2009; 84: 421-427.
38. Sharma AN, Elased KM, Lucot JB. Rosiglitazone treatment reversed depressionbut not psychosis-like behavior of db/db diabetic mice. J Psychopharmacol 2012; 26: 724-732.
39. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009; 106: 232-246.
40. Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natil Acad Sci USA 2001; 98: 12796-12801.
41. Santiago JJ, Ma X, McNaughton LJ, Nickel BE, Bestvater BP, Yu L et al. Preferential accumulation and export of high molecular weight FGF-2 by rat cardiac non-myocytes. Cardiovasc Res 2011; 89: 139-147.
42. Florkiewicz RZ, Baird A, Gonzalez AM. Multiple forms of bFGF: differential nuclear and cell surface localization. Growth Factors 1991; 4: 265-275.
43. Schiera G, Proia P, Alberti C, Mineo M, Savettieri G, Di Liegro I. Neurons produce FGF2 and VEGF and secrete them at least in part by shedding extracellular vesicles. J Cell Mol Med 2007; 11: 1384-1394.
44. Grothe C, Schulze A, Semkova I, Muller-Ostermeyer F, Rege A, Wewetzer K. The high molecular weight fibroblast growth factor-2 isoforms (21,000 mol. wt and 23,000 mol. wt) mediate neurotrophic activity on rat embryonic mesencephalic dopaminergic neurons in vitro. Neuroscience 2000; 100: 73-86.
45. Meisinger C, Grothe C. Differential expression of FGF-2 isoforms in the rat adrenal medulla during postnatal development in vivo. Brain Res 1997; 757: 291-294.
46. Meisinger C, Grothe C. Differential regulation of fibroblast growth factor (FGF)-2 and FGF receptor 1 mRNAs and FGF-2 isoforms in spinal ganglia and sciatic nerve after peripheral nerve lesion. J Neurochem 1997; 68: 1150-1158.
47. Abraham IM, Meerlo P, Luiten PG. Concentration dependent actions of glucocorticoids on neuronal viability and survival. Dose Response 2006; 4: 38-54.
48. Uno H, Tarara R, Else JG, Suleman MA, Sapolsky RM. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci 1989; 9: 1705-1711.
49. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D et al. FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natil Acad Sci USA 2005; 102: 18189-18194.
50. Wagner JP, Black IB, DiCicco-Bloom E. Stimulation of neonatal and adult brain neurogenesis by subcutaneous injection of basic fibroblast growth factor. J Neurosci 1999; 19: 6006-6016.
51. Dhabhar FS, Burke HM, Epel ES, Mellon SH, Rosser R, Reus VI et al. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J Psychiatr Res 2009; 43: 962-969.
52. Mesquita AR, Correia-Neves M, Roque S, Castro AG, Vieira P, Pedrosa J et al. IL-10 modulates depressive-like behavior. J Psychiatr Res 2008; 43: 89-97.
53. Perez JA, Clinton SM, Turner CA, Watson SJ, Akil H. A new role for FGF2 as an endogenous inhibitor of anxiety. J Neurosci 2009; 29: 6379-6387.
54. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science 2012; 338: 72-75.
55. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-809.
56. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011; 476: 458-461.
57. Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G et al. Brain PPARgamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 2011; 17: 618-622.
58. Kheirbek MA, Klemenhagen KC, Sahay A, Hen R. Neurogenesis and generalization: a new approach to stratify and treat anxiety disorders. Nat Neurosci 2012; 15: 1613-1620.